Revance Therapeutics Inc (FRA:RTI)
€ 3.5 -0.08 (-2.23%) Market Cap: 358.58 Mil Enterprise Value: 642.04 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 68/100

Revance Therapeutics Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 08, 2021 / 08:40PM GMT
Release Date Price: €23.4 (+2.63%)
Terence C. Flynn
Goldman Sachs Group, Inc., Research Division - MD

Great. Good afternoon, everybody.

I'm Terence Flynn, the U.S. biopharma analyst at Goldman Sachs, and I'm very pleased to be hosting Revance this afternoon at our virtual conference.

Joining us from the company, we have Mark Foley, President and CEO; Toby Schilke, CFO; and Jessica Serra from the IR team. Thanks so much for being with us. Really appreciate the time today.

Mark, I'll turn it over to you quickly for some opening remarks before we go into the Q&A.

Mark J. Foley
Revance Therapeutics, Inc. - President, CEO & Director

Great. Thanks, Terence, appreciate the opportunity to be here at the conference today.

So maybe a couple of quick framing comments. After sort of 20 or so years of development, we're on the cusp of the approval of our neuromodulator. We recently announced that the FDA will be inspecting our facility before the end of June, and so we're obviously very anxious to get that product into the market initially in aesthetics. And

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot